Low Libido: A Practical Clinical Framework for What to Check

Low libido — reduced sexual desire — is among the most prevalent sexual health complaints across all genders, yet it is underreported, undertreated, and frequently dismissed as purely psychological. The clinical reality is more interesting: desire is a convergence of hormonal, neurological, psychological, relational, and contextual inputs, and a systematic approach identifies modifiable causes in a substantial proportion of cases.

This article outlines a practical clinical framework for evaluating low libido in adults. It is educational information, not medical advice. Because the differential diagnosis is broad and some contributing factors require specific laboratory evaluation and treatment, assessment and management should occur with a qualified clinician.

Defining the problem: hypoactive sexual desire disorder (HSDD)

Hypoactive sexual desire disorder (HSDD) is the formal diagnostic category: persistently low or absent sexual desire that causes personal distress. The distress criterion is important — low desire that does not bother the individual is not a disorder. The DSM-5 separates male HSDD from female sexual interest/arousal disorder (FSIAD), acknowledging that women's desire is more often responsive (arising in the context of stimulation) rather than spontaneous, and that the two can be conflated.

Prevalence estimates vary widely depending on definition, but surveys including the Global Study of Sexual Attitudes and Behaviors (GSSAB) — a multinational survey of approximately 27,500 adults published in Archives of Sexual Behavior — found that lack of sexual interest affected roughly 30–40% of women and 15–25% of men globally, with rates increasing with age.

The hormonal layer: what to measure and what it means

Hormones are a necessary but not sufficient explanation for most cases of low libido. The following are the core hormonal contributors:

Testosterone plays a central role in sexual desire in both sexes. In men, the association between confirmed hypogonadism and reduced libido is well established — and testosterone therapy in confirmed deficiency consistently improves desire. The picture is more complex in women: circulating testosterone levels in women are tenfold lower than in men and harder to measure reliably at low concentrations, yet testosterone is active at androgen receptors in the brain areas involved in motivation and desire.

• The International Society for the Study of Women's Sexual Health (ISSWSH) published a process-of-care consensus (2019, Mayo Clinic Proceedings) supporting the use of testosterone for postmenopausal women with HSDD, based on a systematic review of 36 randomized trials showing consistent improvement in desire, arousal, and orgasm.
• Estrogen deficiency — particularly in perimenopause, menopause, and postpartum states — reduces libido both directly (via central androgen receptor sensitivity) and indirectly (via genitourinary syndrome of menopause causing dyspareunia, which suppresses desire through pain avoidance).
• Elevated prolactin (hyperprolactinemia) suppresses GnRH and downstream sex hormone production. Causes include prolactinomas, antipsychotic medications, and hypothyroidism. Prolactin should be checked in the workup.
• Thyroid dysfunction: Both hypothyroidism and hyperthyroidism impair libido. TSH is a low-yield but inexpensive and frequently relevant screen.

A reasonable initial laboratory panel in adults with low libido includes: morning total testosterone (and free testosterone if SHBG abnormality is suspected), prolactin, TSH, and — in women — consideration of estradiol and FSH if menopausal transition is possible.

Medications as a major underrecognized driver

Medications are among the most common and reversible contributors to low libido, yet they are systematically underexplored in clinical encounters.

Highly relevant drug classes include:

• SSRIs and SNRIs: Sexual dysfunction — including reduced desire, delayed orgasm, and anorgasmia — occurs in an estimated 30–70% of users depending on the agent and dose. Sertraline and paroxetine have higher rates; bupropion, mirtazapine, and vortioxetine have lower rates. Dose reduction, agent switching, or adjunctive strategies (e.g., adding bupropion) are evidence-based options.
• Oral contraceptives and hormonal IUDs: Oral contraceptives raise SHBG, which binds free testosterone and reduces bioavailable androgen. Some women notice a persistent reduction in libido or genital sensation. A 2006 study in Journal of Sexual Medicine found elevated SHBG persisted months after OCP discontinuation. Progestin-only IUDs have lower systemic effect but some users report libido changes.
• Antihypertensives: Beta-blockers and thiazide diuretics are associated with sexual dysfunction. ACE inhibitors and ARBs have more neutral profiles.
• Opioids: Chronic opioid use suppresses the HPG axis and is a significant cause of secondary hypogonadism and low desire in both sexes — substantially underrecognized in pain management contexts.
• Antipsychotics and mood stabilizers: Via prolactin elevation and direct CNS effects.

Psychological and relational contributors

Biology and psychology are not competing explanations — they are co-contributors. The biopsychosocial model is the current standard framework, operationalized in clinical tools like the Brief Sexual Symptom Checklist and addressed in validated psychometric instruments like the Female Sexual Distress Scale and International Index of Erectile Function.

Key psychological contributors:

• Depression and anxiety: Both disorders suppress desire directly, and first-line pharmacological treatments often compound the problem. Cognitive-behavioral therapy for sexual dysfunction has evidence from multiple RCTs.
• Trauma history: Sexual trauma has well-documented effects on desire, arousal, and the felt safety of intimacy. Trauma-informed assessment and referral are appropriate.
• Relationship quality and conflict: Meta-analyses of couples' research consistently find that relationship satisfaction predicts sexual desire more strongly than any single biological variable in long-term partnerships.
• Body image and self-concept: Particularly in women, negative body image is a strong predictor of low desire independent of hormonal status.

When pharmacological treatment is appropriate

Two medications are currently FDA-approved specifically for HSDD in women:

• Flibanserin (Addyi): A non-hormonal daily oral agent that acts on serotonin and dopamine receptors. Modest effect size in RCTs — approximately one additional satisfying sexual event per month over placebo. Approved for premenopausal women with HSDD. Notable drug interaction with alcohol (hypotension risk) and CYP3A4 inhibitors.
• Bremelanotide (Vyleesi): A melanocortin receptor agonist administered as a subcutaneous injection before anticipated sexual activity. Similar modest effect sizes; causes transient nausea and blood pressure elevation.

Neither medication addresses underlying hormonal or relational contributors. In clinical practice, they are adjuncts, not substitutes for a systematic workup.

Key takeaways

• Low libido is a multifactorial symptom, not a diagnosis. A complete evaluation addresses hormonal, medication-related, psychological, and relational contributors — not just one layer.
• Medication review — especially SSRIs, oral contraceptives, and chronic opioids — should be an early and explicit step in the workup.
• Testosterone has the strongest evidence for desire in men with confirmed hypogonadism and moderate evidence in postmenopausal women with HSDD (ISSWSH 2019 consensus, Mayo Clinic Proceedings).
• Depression and relationship quality are independent predictors of desire that require attention alongside any biological intervention.
• Two FDA-approved medications for HSDD exist (flibanserin, bremelanotide) but have modest effect sizes; they are not first-line and do not substitute for systematic evaluation.

References

1. Laumann EO et al. Sexual Problems Among Women and Men Aged 40–80 Years (Global Study of Sexual Attitudes and Behaviors). Archives of Sexual Behavior, 2005
2. Parish SJ et al. International Society for the Study of Women's Sexual Health Process of Care for the Identification of Sexual Concerns and Problems in Women. Mayo Clinic Proceedings, 2019
3. Davis SR et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Journal of Clinical Endocrinology & Metabolism, 2019
4. Basson R et al. Report of the International Consensus Development Conference on Female Sexual Dysfunction. Journal of Urology, 2000
5. Shifren JL et al. Sexual Problems and Distress in United States Women. Obstetrics & Gynecology, 2008
6. Clayton AH et al. Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women (RECONNECT trials). Obstetrics & Gynecology, 2019
7. Simon JA et al. Long-Term Safety and Efficacy of Flibanserin in Women with Hypoactive Sexual Desire Disorder. Journal of Sexual Medicine, 2014